PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma.
MAPK/ERK2 pathway 1
PDGF = platelet-derived growth factor
biomarkers
growth factors (angiogenesis factors)
pediatric cancer and oncology
retinoblastoma
retinoblastoma - epigenetics
targeted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
01
2023
accepted:
12
09
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
epublish
Résumé
Retinoblastoma (RB) is the most common form of eye cancer experienced in childhood. Its aggressive malignancy is associated with excellent survival rates in high-income countries; however, the prognosis in third-world countries is less favorable. Early diagnosis can maximize the patient's visual outcomes and their survival rate. Therapy should be conducted in highly specialized treatment centers. Intravenous chemotherapy (IVC) in bilaterally affected children currently forms the majority of therapy. Local destructive procedures and local chemotherapies such as intra-arterial chemotherapy (IAC) or intravitreal chemotherapy can be taken into consideration depending on the extent and size of the tumor. Nonetheless, children and parents remain under constant stress, revisiting doctors for medical treatment and fearing vision loss and even enucleation of the eye. Adequate molecular patient stratification to improve targeted therapy is still lacking. This retrospective study analyzed formalin-fixed paraffin-embedded specimens from a cohort of 21 RB samples. A total of 11 of those samples showed undifferentiated retinoblastoma (URB) histopathological risk features, and the other 10 showed differentiated retinoblastoma (DRB) histopathological grading. RNA from all samples was isolated and analyzed via digital gene expression patterns. Conductors of cell survival and DNA repair were dominant in the DRB samples. In contrast, the agents responsible for cell-cycle progression and apoptosis were overexpressed in URB samples. Our work reveals the importance of molecular mechanisms within the immune system subjected to histologic subtypes of RB, providing more detailed background on their genetic behavior. This is of great interest for therapeutic strategies, such as targeted immune- and gene-based therapies, for retinoblastoma.
Identifiants
pubmed: 37965463
doi: 10.3389/fonc.2023.1144951
pmc: PMC10642836
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1144951Informations de copyright
Copyright © 2023 Al-Ghazzawi, Wessolly, Dalbah, Ketteler, Kiefer, Bechrakis, Leyla, Ting, Biewald and Mairinger.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Ophthalmol. 1970 Mar;69(3):339-49
pubmed: 4190798
J Natl Cancer Inst. 1983 Jan;70(1):95-104
pubmed: 6571929
J Natl Cancer Inst. 2014 Feb;106(2):djt369
pubmed: 24511106
Cell Cycle. 2016;15(2):283-94
pubmed: 26825229
Prog Mol Biol Transl Sci. 2015;134:503-16
pubmed: 26310174
Am J Ophthalmol. 2015 Apr;159(4):764-76
pubmed: 25528954
Cell. 1995 May 5;81(3):323-30
pubmed: 7736585
Cancers (Basel). 2019 Oct 22;11(10):
pubmed: 31652660
Cancer Genet Cytogenet. 2001 Jul 15;128(2):141-7
pubmed: 11463453
Nat Rev Cancer. 2009 Aug;9(8):537-49
pubmed: 19629069
Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83
pubmed: 21372320
Genes (Basel). 2019 Dec 11;10(12):
pubmed: 31835688
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Cancers (Basel). 2022 Jan 28;14(3):
pubmed: 35158945
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
Elife. 2015 Jun 05;4:e06907
pubmed: 26047463
Cancer Res. 2017 Jul 1;77(13):3666-3671
pubmed: 28446466
Sci Signal. 2012 Nov 13;5(250):pe50
pubmed: 23150879
Cancer Discov. 2016 Apr;6(4):353-67
pubmed: 26658964
Cancer Manag Res. 2019 Nov 12;11:9571-9583
pubmed: 31814759
Cancer Cell. 2011 Aug 16;20(2):260-75
pubmed: 21840489
Physiol Rev. 2001 Apr;81(2):807-69
pubmed: 11274345
Cell Death Dis. 2022 Sep 12;13(9):784
pubmed: 36096885
PLoS One. 2016 Nov 1;11(11):e0165181
pubmed: 27802291
Nature. 2015 Jun 25;522(7557):482-6
pubmed: 25874673
Genes Dev. 2000 Oct 1;14(19):2393-409
pubmed: 11018009
Trends Pharmacol Sci. 1997 Sep;18(9):319-22
pubmed: 9345850
Cancers (Basel). 2020 Sep 29;12(10):
pubmed: 33003565
Cell. 1989 Jan 13;56(1):57-65
pubmed: 2910497
Pediatr Blood Cancer. 2012 Mar;58(3):356-61
pubmed: 21721113
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Nat Commun. 2021 Sep 22;12(1):5578
pubmed: 34552068
JAMA Oncol. 2020 May 1;6(5):685-695
pubmed: 32105305
EBioMedicine. 2015 Jul 08;2(7):660-70
pubmed: 26288838
Nature. 1998 Feb 26;391(6670):859-65
pubmed: 9495340
Expert Opin Investig Drugs. 2010 Jan;19(1):77-91
pubmed: 20001556
Exp Cell Res. 2003 Feb 1;283(1):80-90
pubmed: 12565821
Ophthalmologe. 2020 Apr;117(4):389-402
pubmed: 32206913
Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1545-64
pubmed: 16939974
Lab Invest. 2021 Jun;101(6):701-718
pubmed: 33658609
Sci Rep. 2017 Feb 21;7:43013
pubmed: 28220839
Int Rev Immunol. 1999;18(5-6):485-513
pubmed: 10672498
Biophys Chem. 2015 Oct;205:24-32
pubmed: 26071843